Axomadol
Chemical compound
- None
- US: ?
- (1R,3R,6R)-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol
- 187219-95-0
187219-99-4
- 10221318
- 8396810
- B77S5W28H9
- DTXSID10171992
- Interactive image
- O[C@]2(c1cc(OC)ccc1)C[C@H](O)CC[C@@H]2CN(C)C
InChI
- InChI=1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m1/s1
- Key:LQJLLAOISDVBJM-FMKPAKJESA-N
Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic related to tramadol which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal GmbH for the treatment of chronic, moderate to severe lower back pain and arthrosis.[1][2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.[3]
See also
References
- ^ Ford C (2011-06-30). "Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
- ^ US Abandoned 20100331424, Schiene K, Bloms-Funke P, Bothmer J, Lefeber C, "Use of Axomadol for Treatment of Arthrosis Pain", published 2010-12-30, assigned to Grünenthal GmbH
- ^ Ford C (2011-08-17). "Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
- v
- t
- e
modulators
Calcium blockers |
|
---|---|
Sodium blockers |
|
Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e